Amphastar Pharmaceuticals Inc v. Aventis Pharma SA et al

  1. May 04, 2021

    Sanofi Wins $17.2M Fees, Expenses After Ditching FCA Suit

    Amphastar Pharmaceuticals Inc. must pay Sanofi-Aventis $17.2 million in attorney fees, expenses and interest in its failed False Claims Act suit against the company's predecessor alleging the blood thinner Lovenox was improperly patented, a California federal judge ruled Monday.

  2. November 21, 2017

    Sanofi Wins Fees After Ditching 'Clearly Frivolous' FCA Suit

    Amphastar Pharmaceuticals Inc. must pay Sanofi-Aventis' attorneys' fees for filing a "clearly frivolous" False Claims Act suit against the company's predecessor alleging the blood thinner Lovenox was improperly patented, as Amphastar knew it wasn't eligible to bring such a suit, a California federal judge ruled Monday.

  3. September 19, 2017

    Ex-K&L Gates Atty Escapes Sanctions Over Withheld Evidence

    A California federal judge declined Monday to sanction generic-drug maker Amphastar Pharmaceuticals Inc. and its former K&L Gates attorney for withholding evidence in a since-dismissed False Claims Act suit, saying the counsel acted improperly but not necessarily in bad faith.

  4. April 28, 2017

    Aventis Says K&L Gates Fee Bid Survives High Court Ruling

    Sanofi-Aventis told a federal judge in California on Thursday that its demand for fees from generic-drug maker Amphastar and an ex-K&L Gates LLP attorney for allegedly withholding documents is perfectly consistent with the Supreme Court's recent decision setting boundaries on litigation sanctions.

  5. February 10, 2017

    Sanofi Says Amphastar, Ex-K&L Atty Doctored Evidence

    Sanofi-Aventis urged a federal judge in California on Friday to sanction generic-drug maker Amphastar and its former K&L Gates attorney for altering evidence in a since-dismissed False Claims Act suit, arguing neither the company nor the attorney have been willing to explain how the evidence got altered.

  6. November 23, 2015

    Sanofi Says K&L Gates, Rival Stalling Sanctions In FCA Suit

    Sanofi-Aventis told a California federal judge Friday that a deadline extension requested by Amphastar and its counsel at K&L Gates is just an attempt to stall "explanation for their misconduct" in allegedly doctoring evidence in a False Claims Act suit accusing Sanofi of overcharging the government for an anti-clotting drug.

  7. November 13, 2015

    Sanofi-Aventis Says K&L Gates Can Be Sanctioned In FCA Suit

    Sanofi-Aventis told a California federal judge that he should sanction generic-drug maker Amphastar and its K&L Gates LLP counsel after the judge found that notebooks Amphastar submitted as evidence that it had developed a generic version of Sanofi's anti-clotting drug on its own had been doctored.

  8. July 13, 2015

    Sanofi-Aventis Shakes FCA Suit Over Lovenox

    A California federal judge on Monday tossed generic-drug maker Amphastar Pharmaceutical Inc.'s False Claims Act suit against Sanofi-Aventis SA, finding Amphastar had failed to show it originated the evidence indicating Sanofi's anticoagulant drug Lovenox had been approved under false pretenses.

  9. May 13, 2014

    Sanofi-Aventis Fails To Kill FCA Suit Over Lovenox

    A California federal judge on Tuesday declined to give Sanofi-Aventis SA an early escape from rival Amphastar Pharmaceutical Inc.'s False Claims Act suit alleging the company fraudulently inflated the price of its anticoagulant drug Lovenox, ruling Amphastar had properly disclosed information to the government before filing.

  10. April 19, 2013

    Sanofi Can't Duck Amphastar's FCA Suit Over Lovenox

    A California federal judge on Friday denied Sanofi-Aventis SA's latest bid to toss rival Amphastar Pharmaceuticals Inc.'s False Claims Act suit alleging it fraudulently inflated the price of its Lovenox anti-coagulant drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!